--- title: Simsen announces collaboration with Buzzard Pharmaceuticals description: Simsen announces collaboration with Buzzard Pharmaceuticals image: https://simsendiagnostics.com/hubfs/Buzzard%20news%20bgImage.png --- [Skip to the main content.](https://simsendiagnostics.com/news/simsen-announces-collaboration-with-buzzard-pharmaceuticals#main-content) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) Search [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLinV5ODhlR9zs4gwG7reb92CErn2%2FQC89Jy8Yz9V7BKNXuev6giAejy9xvyrbWimAjQgfX37oPdZ3A7An%2FIDKua3WcVun4EpJkvlYD4eYTcI83sMqal3b2CHDJEQaltXw6PJcLR1yjFibsIu8ghFZiNTUrvCAWr24XcrLqUtK8FpzmQIEE086STy7bcHW7AotL9sEi&webInteractiveContentId=412216133822&portalId=25734893) Toggle Menu Search Toggle Menu [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLinV5ODhlR9zs4gwG7reb92CErn2%2FQC89Jy8Yz9V7BKNXuev6giAejy9xvyrbWimAjQgfX37oPdZ3A7An%2FIDKua3WcVun4EpJkvlYD4eYTcI83sMqal3b2CHDJEQaltXw6PJcLR1yjFibsIu8ghFZiNTUrvCAWr24XcrLqUtK8FpzmQIEE086STy7bcHW7AotL9sEi&webInteractiveContentId=412216133822&portalId=25734893) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) [For clinical trials Pharma and CROs Validate MRD endpoints, cut trial-arm cost, build EU regulatory readiness. Design a trial assay →](https://simsendiagnostics.com/solutions-trials) [For research and labs Translational oncology See signal in paediatric and early-stage samples your current platform misses. Send samples or run SiMSen-Seq in-house. See the signal →](https://simsendiagnostics.com/solutions-research) [For clinics Premium oncology monitoring Detect minimal residual disease ahead of imaging. Logistics across the EU, UK and EEA. Detect relapse earlier →](https://simsendiagnostics.com/solutions-clinic) [Home](https://simsendiagnostics.com/) / [Company](https://simsendiagnostics.com/company-about) / [News](https://simsendiagnostics.com/news) / Simsen announces collaboration with Buzzard Pharmaceuticals [← Back to all news](https://simsendiagnostics.com/news) Customer # Simsen announces collaboration with Buzzard Pharmaceuticals By **Pontus Rehn** February 21, 2025, 3:14:17 PM GMT+01:00 1 min read ![](https://simsendiagnostics.com/hubfs/Buzzard%20news%20bgImage.png) *Gothenburg, 21 February 2025* **Simsen Diagnostics Partners with Buzzard Pharmaceuticals for Isunakinra Colorectal Cancer Trial** Simsen Diagnostics, a leader in ultrasensitive analysis of nucleic acids, is please to announce a collaboration with Buzzard Pharmaceuticals, a Swedish pharmaceutical company, for their Phase IIa, non-randomized, open-label dose expansion trial. The trial will evaluate isunakinra, an IL-1 inhibitor, in combination with pembrolizumab in patients with metastatic or unresectable, locally advanced colorectal cancer.  Buzzard Pharmaceuticals has chosen Simsen Diagnostics as its partner for ultrasensitive ctDNA analysis. Leveraging its proprietary SiMSen-Seq platform, Simsen will deploy its highly sensitive Simsen® Personal solution to monitor circulating tumor DNA (ctDNA) throughout the trial. By enabling personalized tracking of tumor-specific genetic variations through simple blood draws, Simsen® Personal offers the potential to detect minimal residual disease, assess treatment response, identify relapse earlier, and enhance the understanding of disease progression. The primary objectives of the trial are: 1. To determine the safety and tolerability of isunakinra as monotherapy at the RP2D (50mg/day) and in combination therapy with pembrolizumab by evaluating the incidence and severity of adverse events and safety laboratory 2. To evaluate the evidence of clinical benefit in subjects treated with isunakinra including radiological changes and tumor biomarkers at the RP2D In addition, Buzzard wants to explore changes in ctDNA as predictor of response in isunakinra treated patients. The precise and reliable data provided by Simsen® Personal will play a crucial role in guiding these processes and advancing the understanding of isunakinra’s therapeutic potential. *“We are honored to partner with Buzzard Pharmaceuticals in this important trial,”* said Pontus Rehn, CEO of Simsen Diagnostics. *“The application of isunakinra in oncology holds tremendous promise as a potent IL-1 inhibitor, and we are excited to contribute valuable insights that will support Buzzard’s groundbreaking research.”* Maarten de Château, CEO of Buzzard Pharmaceutical, says *“We are delighted to work with Simsen on characterising ctDNA as a marker of therapeutic effect of isunakinra in our trial**. We have found the support given by Simsen in developing the biomarker part of our trial as well as discussions around practical issues to be very constructive and helpful”* **About Simsen Diagnostics:** Simsen Diagnostics is a biotech company that is specialized in ultrasensitive analysis of nucleic acids. Simsen® Personal, the flagship solution, is based on an ultrasensitive sequencing technology capable of detecting minimal residual disease, cancer recurrences, and treatment efficacy, earlier than with any standard-of-care methods. Founded in 2020, Simsen Diagnostics has experienced steady growth, gaining increased recognition from the pharmaceutical industry, CRO’s, researchers and clinics alike. Based in Gothenburg, Sweden, the company is at the forefront of providing innovative services in cancer management and monitoring. Personalized assays. Personalized services. [https://simsendiagnostics.com/](https://simsendiagnostics.com/) **About Buzzard Pharmaceuticals:** Founded in 2016 and based in Stockholm, Sweden, Buzzard Pharmaceuticals specializes in developing innovative oncology treatments. The company’s lead asset, isunakinra, is a potent IL-1 inhibitor re-positioned for cancer indications. Acquired from Eleven Biotherapeutics in 2017, isunakinra is being evaluated in clinical trials for its ability to inhibit IL-1 signaling with high potency. Buzzard was co-founded by Urban Paulsson and Maarten de Château, both experienced leaders in biotech innovation, and is driven by a mission to address unmet needs in cancer care. [https://www.buzzardpharma.com](https://www.buzzardpharma.com/) **Contact:** Pontus Rehn CEO, Simsen Diagnostics pontus.rehn@simsendiagnostics.com #### Share [mailto:?subject=Simsen+announces+collaboration+with+Buzzard+Pharmaceuticals&body=https%3A%2F%2Fsimsendiagnostics.com%2Fnews%2Fsimsen-announces-collaboration-with-buzzard-pharmaceuticals](mailto:?subject=Simsen+announces+collaboration+with+Buzzard+Pharmaceuticals&body=https%3A%2F%2Fsimsendiagnostics.com%2Fnews%2Fsimsen-announces-collaboration-with-buzzard-pharmaceuticals) #### On this page ## More from Simsen ### [June 16, 2026, 3:23:28 PM GMT+02:00 · Corporate Closing the gap between cancer research and patients is partly a question of where the test runs](https://simsendiagnostics.com/news/momentum2026-pre-event) ### [December 17, 2025, 11:57:23 AM GMT+01:00 · Corporate From more treatment to smarter treatment: how tumour‑informed ctDNA monitoring can reduce harm and free capacity in cancer care](https://simsendiagnostics.com/news/from-more-treatment-to-smarter-treatment-how-tumour-informed-ctdna-monitoring-can-reduce-harm-and-free-capacity-in-nordic-cancer-care) ### [November 17, 2025, 3:30:46 PM GMT+01:00 · Corporate Simsen Diagnostics Partners with One-carbon Therapeutics for Groundbreaking ODIN Cancer Trial](https://simsendiagnostics.com/news/simsen-diagnostics-partners-with-one-carbon-pharmaceuticals-for-groundbreaking-odin-cancer-trial) ### [November 11, 2025, 12:03:55 PM GMT+01:00 · Corporate How Pharma Companies Can Leverage Simsen Diagnostic’s Tumour-Informed ctDNA Analysis to Transform Cancer Drug Trials](https://simsendiagnostics.com/news/how-pharma-companies-can-leverage-simsen-diagnostics-tumour-informed-ctdna-analysis-to-transform-cancer-drug-trials) Talk to us ## Running a trial or service that needs this kind of signal? Tell us about your study and your endpoints. A real scientist in CET/CEST will reply. [Request a conversation](https://simsendiagnostics.com/start-a-conversation) [Back to all news](https://simsendiagnostics.com/news) ![full_lockup_white_CMYK kopia](https://simsendiagnostics.com/hs-fs/hubfs/full_lockup_white_CMYK%20kopia.png?width=166&height=45&name=full_lockup_white_CMYK%20kopia.png) **Visiting and postal address:** Pepparedsleden 1 431 53 Mölndal, Sweden **Shipping address:** c/o AstraZeneca R&D Mölndal Pepparedsleden 3 431 53 Mölndal, Sweden PLATFORM PLATFORM - [Platform overview](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) SOLUTIONS SOLUTIONS - [For clinical trials](https://simsendiagnostics.com/solutions-trials) - [For research and labs](https://simsendiagnostics.com/solutions-research) - [For clinics](https://simsendiagnostics.com/solutions-clinic) - [Solutions overview](https://simsendiagnostics.com/solutions-overview) COMPANY COMPANY - [About](https://simsendiagnostics.com/company-about) - [News](https://simsendiagnostics.com/news) - [Team](https://simsendiagnostics.com/company-team) - [Contact](https://simsendiagnostics.com/company-contact) - [Privacy policy](https://simsendiagnostics.com/legal-privacy-policy) - [Cookie Policy](https://simsendiagnostics.com/legal-cookie-policy) - [Terms of use](https://simsendiagnostics.com/legal-terms-of-use) © 2026 Simsen Diagnostics AB, All rights reserved. [Linkedin](https://www.linkedin.com/company/simsendiagnostics) Return to top ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Pontus Rehn", "url" : "https://simsendiagnostics.com/news/author/pontus-rehn" }, "dateModified" : "2025-02-21T14:18:52.322Z", "datePublished" : "2025-02-21T14:14:17.000Z", "headline" : "Simsen announces collaboration with Buzzard Pharmaceuticals", "image" : [ "https://simsendiagnostics.com/hubfs/Buzzard%20news%20bgImage.png" ], "mainEntityOfPage" : { "@id" : "https://simsendiagnostics.com/news/simsen-announces-collaboration-with-buzzard-pharmaceuticals", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://simsendiagnostics.com/hubfs/SD_logo%20medium-2.png" }, "name" : "Simsen Diagnostics AB" } } ```